tetano
Editor, Senior Moderator
ACS Infect Dis. 2016 Jun 10;2(6):382-92. doi: 10.1021/acsinfecdis.6b00041. Epub 2016 May 5.
[h=1]Therapeutic Potential of Spirooxindoles as Antiviral Agents.[/h] Ye N[SUP]1[/SUP], Chen H[SUP]1[/SUP], Wold EA[SUP]1[/SUP], Shi PY[SUP]1[/SUP], Zhou J[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antiviral therapeutics with profiles of high potency, low resistance, panserotype, and low toxicity remain challenging, and obtaining such agents continues to be an active area of therapeutic development. Due to their unique three-dimensional structural features, spirooxindoles have been identified as privileged chemotypes for antiviral drug development. Among them, spiro-pyrazolopyridone oxindoles have been recently reported as potent inhibitors of dengue virus NS4B, leading to the discovery of an orally bioavailable preclinical candidate (R)-44 with excellent in vivo efficacy in a dengue viremia mouse model. This review highlights recent advances in the development of biologically active spirooxindoles for their antiviral potential, primarily focusing on the structure-activity relationships (SARs) and modes of action, as well as future directions to achieve more potent analogues toward a viable antiviral therapy.
[h=4]KEYWORDS:[/h] DENV; HIV; RSV; antiviral agents; influenza virus; spirooxindoles
PMID: 27627626 DOI: 10.1021/acsinfecdis.6b00041
[PubMed - in process]
[h=1]Therapeutic Potential of Spirooxindoles as Antiviral Agents.[/h] Ye N[SUP]1[/SUP], Chen H[SUP]1[/SUP], Wold EA[SUP]1[/SUP], Shi PY[SUP]1[/SUP], Zhou J[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antiviral therapeutics with profiles of high potency, low resistance, panserotype, and low toxicity remain challenging, and obtaining such agents continues to be an active area of therapeutic development. Due to their unique three-dimensional structural features, spirooxindoles have been identified as privileged chemotypes for antiviral drug development. Among them, spiro-pyrazolopyridone oxindoles have been recently reported as potent inhibitors of dengue virus NS4B, leading to the discovery of an orally bioavailable preclinical candidate (R)-44 with excellent in vivo efficacy in a dengue viremia mouse model. This review highlights recent advances in the development of biologically active spirooxindoles for their antiviral potential, primarily focusing on the structure-activity relationships (SARs) and modes of action, as well as future directions to achieve more potent analogues toward a viable antiviral therapy.
[h=4]KEYWORDS:[/h] DENV; HIV; RSV; antiviral agents; influenza virus; spirooxindoles
PMID: 27627626 DOI: 10.1021/acsinfecdis.6b00041
[PubMed - in process]